GUTS Fractyl Health
- 6.900
- +0.120+1.77%
- 6.710
- -0.190-2.75%
Fractyl Health News
Fractyl Health to Present New Preclinical Obesity Data From Rejuva Platform at the American Diabetes Association's 84th Scientific Sessions
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2
Fractyl Health Presents Compelling Preclinical Data From Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p
Bank of America Securities Reaffirms Their Buy Rating on Fractyl Health, Inc. (GUTS)
Earnings Call Summary | Fractyl Health(GUTS.US) Q1 2024 Earnings Conference
The following is a summary of the Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript:Financial Performance:Fractyl Health generated revenue from its commercial pilot in Germany in Q1 2024.Re
Express News | Fractyl Health Q1 2024 GAAP EPS $(0.17) Up From $(7.87) YoY, Sales $33.000K Up From $5.000K YoY
Fractyl Health | 10-Q: Quarterly report
Express News | Fractyl Health: Sees Start of Remain-1 Pivotal Study on Weight Maintenance in Patients With Obesity After Discontinuation of GLP-1 Based Drugs in H2
Earnings Flash (GUTS) FRACTYL HEALTH Reports Q1 Revenue $33,000
04:01 PM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (GUTS) FRACTYL HEALTH Reports Q1 Revenue $33,000
Fractyl Health 1Q Rev $33,000 >GUTS
Fractyl Health 1Q Rev $33,000 >GUTS
Express News | Fractyl Health Inc: Topline Data From Revitalize-1 Pivotal Study in Patients With Inadequately Controlled T2D Anticipated in Q4 2024
Express News | Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Press Release: Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of
Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes
Fractyl Health (GUTS) said Monday that six-month follow-up data from its German real-world registry study of Revita in patients with type 2 diabetes showed sustained or improved weight loss and better
Express News | Fractyl Health Inc: No Device- or Procedure-Related Serious Adverse Events Have Been Observed to Date in Any Registry Participant
Express News | Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
BURLINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2
Express News | Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
Fractyl Health, Inc.'s (NASDAQ:GUTS) Largest Shareholders Are Private Equity Firms With 52% Ownership, Individual Investors Own 30%
Express News | Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (Ddw) 2024 Conference and the German Diabetes Association (Ddg) Annual Meeting
Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday. Shares of Intel Corporation (NASDAQ:INTC) fell sharply in today's pre-market trading after th
Analysis
Price Target
No Data
